Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This research is being done to study the efficacy and safety of unrelated umbilical cord
blood stem cell microtransplantation combined with azacitidine(AZA) based treatment for
advanced myelodysplastic syndromes(MDS), Chronic myelomonocytic leukemia-2(CMML-2) and
secondary acute myeloid leukemia(sAML). The study protocol involved unrelated umbilical cord
blood stem cell combined with azacitidine based treatment, which including azacitidine alone
and azacitidine plus a targeted agent or chemotherapy agent.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University